Skip to content 
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, a viral vaccine product candidate for targeting Cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark. more
| Time Frame | EVAX | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 5.66% | 0.06% | -2.06% |
| 1-Month Return | -33.47% | -2.06% | -2.06% |
| 3-Month Return | -46.33% | 6.1% | 1.11% |
| 6-Month Return | 18.73% | 18.64% | 7.13% |
| 1-Year Return | 22.18% | 5.25% | 11.74% |
| 3-Year Return | -96.27% | 17.35% | 65.43% |
| 5-Year Return | -99.32% | 33.7% | 73.53% |
| 10-Year Return | -99.32% | 143.77% | 266.66% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | 73.00K | 3.34M | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":2.18,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Cost of Revenue | 105.72K | 343.45K | 571.32K | 112.00 | - | [{"date":"2020-12-31","value":18.5,"profit":true},{"date":"2021-12-31","value":60.12,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":0.02,"profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Gross Profit | (105.72K) | (343.45K) | (571.32K) | 73.00K | 3.34M | [{"date":"2020-12-31","value":-3.16,"profit":false},{"date":"2021-12-31","value":-10.27,"profit":false},{"date":"2022-12-31","value":-17.08,"profit":false},{"date":"2023-12-31","value":2.18,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | 100.00% | 100.00% | [{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Operating Expenses | 16.57M | 25.83M | 25.26M | 22.27M | 18.08M | [{"date":"2020-12-31","value":64.13,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.79,"profit":true},{"date":"2023-12-31","value":86.2,"profit":true},{"date":"2024-12-31","value":69.97,"profit":true}] |
| Operating Income | (16.57M) | (25.83M) | (25.26M) | (22.20M) | (14.73M) | [{"date":"2020-12-31","value":-1656800000,"profit":false},{"date":"2021-12-31","value":-2583400000,"profit":false},{"date":"2022-12-31","value":-2526400000,"profit":false},{"date":"2023-12-31","value":-2219700000,"profit":false},{"date":"2024-12-31","value":-1473200000,"profit":false}] |
| Total Non-Operating Income/Expense | (14.00K) | 2.25M | 2.65M | (3.73M) | 2.67M | [{"date":"2020-12-31","value":-0.52,"profit":false},{"date":"2021-12-31","value":84.23,"profit":true},{"date":"2022-12-31","value":99.14,"profit":true},{"date":"2023-12-31","value":-139.68,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
| Pre-Tax Income | (16.57M) | (24.71M) | (23.94M) | (22.91M) | (11.36M) | [{"date":"2020-12-31","value":-1657500000,"profit":false},{"date":"2021-12-31","value":-2471000000,"profit":false},{"date":"2022-12-31","value":-2394100000,"profit":false},{"date":"2023-12-31","value":-2291500000,"profit":false},{"date":"2024-12-31","value":-1135500000,"profit":false}] |
| Income Taxes | (1.56M) | (178.00K) | (772.00K) | (790.00K) | (788.00K) | [{"date":"2020-12-31","value":-155700000,"profit":false},{"date":"2021-12-31","value":-17800000,"profit":false},{"date":"2022-12-31","value":-77200000,"profit":false},{"date":"2023-12-31","value":-79000000,"profit":false},{"date":"2024-12-31","value":-78800000,"profit":false}] |
| Income After Taxes | (15.02M) | (24.53M) | (23.17M) | (22.13M) | (10.57M) | [{"date":"2020-12-31","value":-1501800000,"profit":false},{"date":"2021-12-31","value":-2453200000,"profit":false},{"date":"2022-12-31","value":-2316900000,"profit":false},{"date":"2023-12-31","value":-2212500000,"profit":false},{"date":"2024-12-31","value":-1056700000,"profit":false}] |
| Income From Continuous Operations | (15.02M) | (24.53M) | (23.17M) | (24.47M) | (10.57M) | [{"date":"2020-12-31","value":-1501800000,"profit":false},{"date":"2021-12-31","value":-2453200000,"profit":false},{"date":"2022-12-31","value":-2316900000,"profit":false},{"date":"2023-12-31","value":-2447400000,"profit":false},{"date":"2024-12-31","value":-1056700000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (15.02M) | (24.53M) | (23.17M) | (22.13M) | (10.57M) | [{"date":"2020-12-31","value":-1501800000,"profit":false},{"date":"2021-12-31","value":-2453200000,"profit":false},{"date":"2022-12-31","value":-2316900000,"profit":false},{"date":"2023-12-31","value":-2212500000,"profit":false},{"date":"2024-12-31","value":-1056700000,"profit":false}] |
| EPS (Diluted) | (0.19) | (1.25) | (3.59) | (2.26) | 0.07 | [{"date":"2020-12-31","value":-271.43,"profit":false},{"date":"2021-12-31","value":-1785.71,"profit":false},{"date":"2022-12-31","value":-5128.57,"profit":false},{"date":"2023-12-31","value":-3228.57,"profit":false},{"date":"2024-12-31","value":100,"profit":true}] |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| EVAX | |
|---|---|
| ROA (LTM) | -25.62% |
| ROE (LTM) | -64.99% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| EVAX | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.44 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.56 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| EVAX | |
|---|---|
| Trailing PE | NM |
| Forward PE | 3.57 |
| P/S (TTM) | 3.17 |
| P/B | 4.81 |
| EV/R | 2.96 |
| EV/Ebitda | NM |
Evaxion Biotech AS (EVAX) share price today is $3.36
Yes, Indians can buy shares of Evaxion Biotech AS (EVAX) on Vested. To buy
Yes, you can purchase fractional shares of Evaxion Biotech AS (EVAX) via the Vested app. You can start investing in Evaxion Biotech AS (EVAX) with a minimum investment of $1.
You can invest in shares of Evaxion Biotech AS (EVAX) via Vested in three simple steps:
The 52-week high price of Evaxion Biotech AS (EVAX) is $12.15. The 52-week low price of Evaxion Biotech AS (EVAX) is $1.2.
The price-to-earnings (P/E) ratio of Evaxion Biotech AS (EVAX) is
The price-to-book (P/B) ratio of Evaxion Biotech AS (EVAX) is 4.81
The dividend yield of Evaxion Biotech AS (EVAX) is 0.00%
The market capitalization of Evaxion Biotech AS (EVAX) is $24.27M
The stock symbol (or ticker) of Evaxion Biotech AS is EVAX
Consider the share price of Evaxion Biotech AS as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Evaxion Biotech AS has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Evaxion Biotech AS shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Evaxion Biotech AS stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Evaxion Biotech AS and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Evaxion Biotech AS stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
